817 Shares in Humana Inc. (NYSE:HUM) Purchased by Sendero Wealth Management LLC

Sendero Wealth Management LLC acquired a new position in shares of Humana Inc. (NYSE:HUM) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 817 shares of the insurance provider’s stock, valued at approximately $283,000.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in Humana during the 4th quarter worth approximately $676,800,000. Sanders Capital LLC bought a new position in Humana during the fourth quarter worth about $489,300,000. Putnam Investments LLC raised its stake in Humana by 550.3% in the 4th quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock worth $400,808,000 after purchasing an additional 740,858 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after purchasing an additional 402,559 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Humana by 39.3% in the 3rd quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock valued at $331,743,000 after purchasing an additional 192,546 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Up 2.9 %

HUM traded up $10.63 during midday trading on Friday, hitting $373.61. 5,489,736 shares of the company were exchanged, compared to its average volume of 1,829,337. The firm’s 50 day moving average price is $343.78 and its 200-day moving average price is $351.97. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $530.54. The firm has a market capitalization of $45.02 billion, a P/E ratio of 23.26, a P/E/G ratio of 2.09 and a beta of 0.53. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.38 earnings per share. As a group, equities analysts forecast that Humana Inc. will post 16.27 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is presently 22.04%.

Analyst Ratings Changes

HUM has been the subject of a number of analyst reports. Morgan Stanley started coverage on shares of Humana in a research report on Monday. They issued an “equal weight” rating and a $374.00 price target for the company. Bank of America increased their target price on Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a report on Monday, May 20th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $360.00 price target on shares of Humana in a research note on Wednesday, June 12th. UBS Group reduced their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. Finally, Royal Bank of Canada dropped their target price on shares of Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Fourteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average target price of $409.55.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.